PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD.
Stefania GrimaudoStefano BartesaghiRaffaela RamettaFabio MarraRosellina Margherita MancinaJussi PihlajamäkiDorota Kakol-PalmAnne-Christine AndréassonPaola DongiovanniAnna Ludovica FracanzaniGiulia LoriVille MännistöGiovanni PellegriniMohammad Bohlooly-YGrazia PennisiRosaria Maria PipitoneRocco SpagnuoloAntonio CraxìDaniel LindénLuca Vittorio ValentiStefano RomeoSalvatore PettaPublished in: Liver international : official journal of the International Association for the Study of the Liver (2020)
In individuals at risk of NASH, PCSK9 was induced with hepatic fat accumulation and PCSK9 rs11591147 LOF variant was protective against liver steatosis, NASH and fibrosis, suggesting that PCSK9 inhibition may be a new therapeutic strategy to treat NASH.